Heterogeneous chemosensitivity of breast cancer determined by adeonsine triphosphate based chemotherapy response assay

Suk Kyung Choi, Jeong Joon, Seung Ah Lee, Seung Hyun Hwang, Sung Gwe Ahn, Woo Hee Jung, Hy De Lee

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: Breast cancer is heterogeneous disease and the response to chemotherapeutic agents is also heterogeneous from patient to patient. Chemotherapy response assay is in vitro test that is performed to evaluate the degree of tumor growth inhibition by chemotherapy drugs. In this study, we performed the chemotherapy response assay using adenosine triphosphate (ATP-CRA) in breast cancer patients and assessed the clinical availability. Methods: Sixty five breast cancer patients were enrolled in this study. Cancer cells were evenly divided and treated with commonly used chemotherapeutic drugs in breast cancer (doxorubicin, epirubicin, 5-fluorouracil, paclitaxel, docetaxel, vinorelbine, and gemcitabine). To verify in vitro ATP-CRA indirectly, we analyzed the correlation between cell death rate (CDR) of doxorubicin and epirubicin, and between doxorubicin and paclitaxel. We also analyzed the mean CDR of doxorubicin, epirubicin and paclitaxel by HER2 status. Results: We could successfully perform the ATP-CRA in 60 patients (95.2%). In all cases, we can get the results within 7 days. The range of CDR was very wide, from 0 to more than 50%, except gemcitabine. Epirubicin showed the highest mean CDR (39.9%) and doxorubicin, paclitaxel in order. According to the chemosensitivity index, paclitaxel is the most frequently first-ranked and doxorubicin, epirubicin in order. Correlation coefficient between the cell death rate of doxorubicin and epirubicin is 0.4210 and 0.1299 between paclitaxel and doxorubicin. In HER2 positive group, mean CDR of paclitaxel, epirubicin and doxorubicin washigher than in HER2 negative group, even though epirubicin and doxorubicin were not statistically significant (p=0.018, p= 0.114, p=0.311, respectively). Conclusion: ATP-CRA showed heterogeneous results in individual patients. ATP-CRA was successful and can be performed within short time period. According to our in vitro study, it showed similar results with in vivo study but for the clinical use, the prospective andomized controlled trial should be preceded.

Original languageEnglish
Pages (from-to)180-186
Number of pages7
JournalJournal of Breast Cancer
Volume13
Issue number2
DOIs
Publication statusPublished - 2010 Jun 1

Fingerprint

Epirubicin
Doxorubicin
Paclitaxel
Breast Neoplasms
Drug Therapy
Cell Death
Adenosine Triphosphate
gemcitabine
Mortality
docetaxel
triphosphoric acid
Fluorouracil
Pharmaceutical Preparations
Neoplasms
Growth

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Choi, Suk Kyung ; Joon, Jeong ; Lee, Seung Ah ; Hwang, Seung Hyun ; Ahn, Sung Gwe ; Jung, Woo Hee ; Lee, Hy De. / Heterogeneous chemosensitivity of breast cancer determined by adeonsine triphosphate based chemotherapy response assay. In: Journal of Breast Cancer. 2010 ; Vol. 13, No. 2. pp. 180-186.
@article{4ca59df776e749518c423c2c9b1eb94c,
title = "Heterogeneous chemosensitivity of breast cancer determined by adeonsine triphosphate based chemotherapy response assay",
abstract = "Purpose: Breast cancer is heterogeneous disease and the response to chemotherapeutic agents is also heterogeneous from patient to patient. Chemotherapy response assay is in vitro test that is performed to evaluate the degree of tumor growth inhibition by chemotherapy drugs. In this study, we performed the chemotherapy response assay using adenosine triphosphate (ATP-CRA) in breast cancer patients and assessed the clinical availability. Methods: Sixty five breast cancer patients were enrolled in this study. Cancer cells were evenly divided and treated with commonly used chemotherapeutic drugs in breast cancer (doxorubicin, epirubicin, 5-fluorouracil, paclitaxel, docetaxel, vinorelbine, and gemcitabine). To verify in vitro ATP-CRA indirectly, we analyzed the correlation between cell death rate (CDR) of doxorubicin and epirubicin, and between doxorubicin and paclitaxel. We also analyzed the mean CDR of doxorubicin, epirubicin and paclitaxel by HER2 status. Results: We could successfully perform the ATP-CRA in 60 patients (95.2{\%}). In all cases, we can get the results within 7 days. The range of CDR was very wide, from 0 to more than 50{\%}, except gemcitabine. Epirubicin showed the highest mean CDR (39.9{\%}) and doxorubicin, paclitaxel in order. According to the chemosensitivity index, paclitaxel is the most frequently first-ranked and doxorubicin, epirubicin in order. Correlation coefficient between the cell death rate of doxorubicin and epirubicin is 0.4210 and 0.1299 between paclitaxel and doxorubicin. In HER2 positive group, mean CDR of paclitaxel, epirubicin and doxorubicin washigher than in HER2 negative group, even though epirubicin and doxorubicin were not statistically significant (p=0.018, p= 0.114, p=0.311, respectively). Conclusion: ATP-CRA showed heterogeneous results in individual patients. ATP-CRA was successful and can be performed within short time period. According to our in vitro study, it showed similar results with in vivo study but for the clinical use, the prospective andomized controlled trial should be preceded.",
author = "Choi, {Suk Kyung} and Jeong Joon and Lee, {Seung Ah} and Hwang, {Seung Hyun} and Ahn, {Sung Gwe} and Jung, {Woo Hee} and Lee, {Hy De}",
year = "2010",
month = "6",
day = "1",
doi = "10.4048/jbc.2010.13.2.180",
language = "English",
volume = "13",
pages = "180--186",
journal = "Journal of Breast Cancer",
issn = "1738-6756",
publisher = "Korean Breast Cancer Society",
number = "2",

}

Heterogeneous chemosensitivity of breast cancer determined by adeonsine triphosphate based chemotherapy response assay. / Choi, Suk Kyung; Joon, Jeong; Lee, Seung Ah; Hwang, Seung Hyun; Ahn, Sung Gwe; Jung, Woo Hee; Lee, Hy De.

In: Journal of Breast Cancer, Vol. 13, No. 2, 01.06.2010, p. 180-186.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Heterogeneous chemosensitivity of breast cancer determined by adeonsine triphosphate based chemotherapy response assay

AU - Choi, Suk Kyung

AU - Joon, Jeong

AU - Lee, Seung Ah

AU - Hwang, Seung Hyun

AU - Ahn, Sung Gwe

AU - Jung, Woo Hee

AU - Lee, Hy De

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Purpose: Breast cancer is heterogeneous disease and the response to chemotherapeutic agents is also heterogeneous from patient to patient. Chemotherapy response assay is in vitro test that is performed to evaluate the degree of tumor growth inhibition by chemotherapy drugs. In this study, we performed the chemotherapy response assay using adenosine triphosphate (ATP-CRA) in breast cancer patients and assessed the clinical availability. Methods: Sixty five breast cancer patients were enrolled in this study. Cancer cells were evenly divided and treated with commonly used chemotherapeutic drugs in breast cancer (doxorubicin, epirubicin, 5-fluorouracil, paclitaxel, docetaxel, vinorelbine, and gemcitabine). To verify in vitro ATP-CRA indirectly, we analyzed the correlation between cell death rate (CDR) of doxorubicin and epirubicin, and between doxorubicin and paclitaxel. We also analyzed the mean CDR of doxorubicin, epirubicin and paclitaxel by HER2 status. Results: We could successfully perform the ATP-CRA in 60 patients (95.2%). In all cases, we can get the results within 7 days. The range of CDR was very wide, from 0 to more than 50%, except gemcitabine. Epirubicin showed the highest mean CDR (39.9%) and doxorubicin, paclitaxel in order. According to the chemosensitivity index, paclitaxel is the most frequently first-ranked and doxorubicin, epirubicin in order. Correlation coefficient between the cell death rate of doxorubicin and epirubicin is 0.4210 and 0.1299 between paclitaxel and doxorubicin. In HER2 positive group, mean CDR of paclitaxel, epirubicin and doxorubicin washigher than in HER2 negative group, even though epirubicin and doxorubicin were not statistically significant (p=0.018, p= 0.114, p=0.311, respectively). Conclusion: ATP-CRA showed heterogeneous results in individual patients. ATP-CRA was successful and can be performed within short time period. According to our in vitro study, it showed similar results with in vivo study but for the clinical use, the prospective andomized controlled trial should be preceded.

AB - Purpose: Breast cancer is heterogeneous disease and the response to chemotherapeutic agents is also heterogeneous from patient to patient. Chemotherapy response assay is in vitro test that is performed to evaluate the degree of tumor growth inhibition by chemotherapy drugs. In this study, we performed the chemotherapy response assay using adenosine triphosphate (ATP-CRA) in breast cancer patients and assessed the clinical availability. Methods: Sixty five breast cancer patients were enrolled in this study. Cancer cells were evenly divided and treated with commonly used chemotherapeutic drugs in breast cancer (doxorubicin, epirubicin, 5-fluorouracil, paclitaxel, docetaxel, vinorelbine, and gemcitabine). To verify in vitro ATP-CRA indirectly, we analyzed the correlation between cell death rate (CDR) of doxorubicin and epirubicin, and between doxorubicin and paclitaxel. We also analyzed the mean CDR of doxorubicin, epirubicin and paclitaxel by HER2 status. Results: We could successfully perform the ATP-CRA in 60 patients (95.2%). In all cases, we can get the results within 7 days. The range of CDR was very wide, from 0 to more than 50%, except gemcitabine. Epirubicin showed the highest mean CDR (39.9%) and doxorubicin, paclitaxel in order. According to the chemosensitivity index, paclitaxel is the most frequently first-ranked and doxorubicin, epirubicin in order. Correlation coefficient between the cell death rate of doxorubicin and epirubicin is 0.4210 and 0.1299 between paclitaxel and doxorubicin. In HER2 positive group, mean CDR of paclitaxel, epirubicin and doxorubicin washigher than in HER2 negative group, even though epirubicin and doxorubicin were not statistically significant (p=0.018, p= 0.114, p=0.311, respectively). Conclusion: ATP-CRA showed heterogeneous results in individual patients. ATP-CRA was successful and can be performed within short time period. According to our in vitro study, it showed similar results with in vivo study but for the clinical use, the prospective andomized controlled trial should be preceded.

UR - http://www.scopus.com/inward/record.url?scp=77954707675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954707675&partnerID=8YFLogxK

U2 - 10.4048/jbc.2010.13.2.180

DO - 10.4048/jbc.2010.13.2.180

M3 - Article

AN - SCOPUS:77954707675

VL - 13

SP - 180

EP - 186

JO - Journal of Breast Cancer

JF - Journal of Breast Cancer

SN - 1738-6756

IS - 2

ER -